{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:58:40Z","timestamp":1781110720382,"version":"3.54.1"},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T00:00:00Z","timestamp":1379635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Histological transformation (<jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content>) is a major cause of morbidity and mortality in patients with indolent non\u2010<jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>odgkin lymphoma (<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>). The multicentre <jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>ational <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>ancer <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>omprehensive <jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>etwork database for <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> provides a unique opportunity to investigate the natural history of <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content> in the rituximab era. 118 patients with biopsy\u2010confirmed indolent lymphoma and subsequent biopsy\u2010confirmed <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content> were identified. Treatments for <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content> included autologous stem\u2010cell transplant (auto\u2010<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>) (<jats:italic>n<\/jats:italic>\u00a0=\u00a050), allogeneic <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> (allo\u2010<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>) (<jats:italic>n<\/jats:italic>\u00a0=\u00a018), and treatment without transplant (<jats:italic>n<\/jats:italic>\u00a0=\u00a050). The 2\u2010year overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) for the entire cohort was 68%. For auto\u2010<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> patients aged \u226460\u00a0years (<jats:italic>n<\/jats:italic>\u00a0=\u00a024), the 2\u2010year <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> was 74%. For non\u2010transplanted patients aged \u226460\u00a0years (<jats:italic>n<\/jats:italic>\u00a0=\u00a019), the 2\u2010year <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> was 59%. The 2\u2010year <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> of patients na\u00efve to chemotherapy prior to <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content> was superior to patients who were exposed to chemotherapy prior to <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content> (100% vs. 35%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b703). In this largest prospective cohort of patients of strictly defined <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content> in the rituximab era, the natural history of <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content> appears more favourable than historical studies. Younger patients who were not exposed to chemotherapy prior to <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content> experienced a prolonged survival even without transplantation. This study serves as a benchmark for future trials of novel approaches for <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content> in the Rituximab era.<\/jats:p>","DOI":"10.1111\/bjh.12570","type":"journal-article","created":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T01:02:24Z","timestamp":1381539744000},"page":"487-495","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Transformed non\u2010Hodgkin lymphoma in the rituximab era: analysis of the <scp>NCCN<\/scp> outcomes database"],"prefix":"10.1111","volume":"163","author":[{"given":"Makiko","family":"Ban\u2010Hoefen","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology James P. Wilmot Cancer Center University of Rochester Rochester NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Vanderplas","sequence":"additional","affiliation":[{"name":"Department of Biostatistics City of Hope Comprehensive Cancer Center Duarte CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L.","family":"Crosby\u2010Thompson","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Dana\u2010Farber Cancer Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Abel","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Dana\u2010Farber Cancer Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Roswell Park Cancer Institute Buffalo NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Robert H. Lurie Comprehensive Cancer Center Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology University of Michigan Comprehensive Cancer Center Ann Arbor MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology James P. Wilmot Cancer Center University of Rochester Rochester NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Millenson","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auayporn P.","family":"Nademanee","sequence":"additional","affiliation":[{"name":"Department of Biostatistics City of Hope Comprehensive Cancer Center Duarte CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Memorial Sloan\u2010Kettering Cancer Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Niland","sequence":"additional","affiliation":[{"name":"Department of Biostatistics City of Hope Comprehensive Cancer Center Duarte CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Dana\u2010Farber Cancer Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology James P. Wilmot Cancer Center University of Rochester Rochester NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,9,20]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"790","article-title":"Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma","volume":"110","author":"Al\u2010Tourah A.J.","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0283"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705178"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds433"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1587"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.532"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174839"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02705.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08781.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06439.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05755.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08519.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.9217"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008349427337"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.5800"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.1999.v5.pm10465106"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.1648"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.015"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4061"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00628.x"},{"key":"e_1_2_9_24_1","first-page":"3272","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"26","author":"Link B.K.","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2119"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.3260"},{"key":"e_1_2_9_27_1","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1182\/blood.V112.11.4459.4459","article-title":"Autologous stem cell transplantation is superior to myeloablative allogeneic SCT as a salvage therapy for patients with refractory\/relapsed transformed lymphoma [abstract]","volume":"112","author":"Ramadan K.M.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.07.003"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.5477"},{"key":"e_1_2_9_30_1","first-page":"1405","article-title":"Aberrant somatic hypermutation in transformation of follicular lymphoma and CLL to diffuse large B cell lymphoma","volume":"91","author":"Rossi D.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.04.009"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.503"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.3328"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.0693"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.727"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08991.x"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1726"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12570","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T23:41:30Z","timestamp":1696290090000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,20]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1111\/bjh.12570"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12570","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,20]]},"assertion":[{"value":"2013-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-09-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}